JO3787B1 - أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها - Google Patents

أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها

Info

Publication number
JO3787B1
JO3787B1 JOP/2013/0072A JOP20130072A JO3787B1 JO 3787 B1 JO3787 B1 JO 3787B1 JO P20130072 A JOP20130072 A JO P20130072A JO 3787 B1 JO3787 B1 JO 3787B1
Authority
JO
Jordan
Prior art keywords
antibodies
methods
cell proliferation
human anti
human
Prior art date
Application number
JOP/2013/0072A
Other languages
English (en)
Inventor
Wheeler John
Sweet Raymond
Chen John
Fransson Johan
Rycyzyn Michael
Scully Michael
Malia Thomas
Carlos Almagro Juan
Hamel Damon
Teplyakov Alexey
Fursov Natalie
Obmolova Galina
Ort Tatiana
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of JO3787B1 publication Critical patent/JO3787B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

أجسام مضادة آدمية موجهة مناعيا ضد <span dir="LTR">CD27</span> الآدمي يمكن أن تمنع إرتباط <span dir="LTR">CD27</span> مع الليجاند الخاص به <span dir="LTR">CD70</span> ويعادل النشاط البيولوجي لـ <span dir="LTR">CD27</span> بما يتضمن على سبيل المثال وليس الحصر الإشارة بداخل الخلية لـ <span dir="LTR">CD27</span>، تكاثر الخلايا <span dir="LTR">T</span> وتنشيط تكاثر وتمايز الخلايا <span dir="LTR">B</span>، وتكوين الخلايا المكونة لخلايا البلازما وتخفيف استجابات الجسم المضاد، وتنشيط خلايا الأورام عن طريق <span dir="LTR">CD70</span>، وإنتاج مركبات وسيطة قابلة للذوبان من الخلايا <span dir="LTR">T </span> و<span dir="LTR">B</span>. تفيد تلك الأجسام المضادة في تشخيص أو علاج الحالات و الأمراض التي ترتبط بنشاط <span dir="LTR">CD27</span>.
JOP/2013/0072A 2012-03-15 2013-03-14 أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها JO3787B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261611332P 2012-03-15 2012-03-15

Publications (1)

Publication Number Publication Date
JO3787B1 true JO3787B1 (ar) 2021-01-31

Family

ID=49157853

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0072A JO3787B1 (ar) 2012-03-15 2013-03-14 أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها

Country Status (28)

Country Link
US (6) US9102737B2 (ar)
EP (1) EP2825200A4 (ar)
JP (1) JP6487839B2 (ar)
KR (1) KR102153374B1 (ar)
CN (1) CN104284678B (ar)
AR (1) AR090356A1 (ar)
AU (1) AU2013232087B2 (ar)
BR (2) BR122020002414B1 (ar)
CA (1) CA2867299C (ar)
CL (1) CL2014002416A1 (ar)
CO (1) CO7071095A2 (ar)
CR (1) CR20140415A (ar)
EA (1) EA030828B1 (ar)
EC (1) ECSP14018641A (ar)
GT (1) GT201400193A (ar)
HK (1) HK1206251A1 (ar)
JO (1) JO3787B1 (ar)
MX (1) MX363946B (ar)
MY (1) MY175224A (ar)
NZ (1) NZ629697A (ar)
PE (1) PE20142242A1 (ar)
PH (2) PH12014502011B1 (ar)
SG (2) SG11201405437QA (ar)
TW (2) TW201730214A (ar)
UA (1) UA121844C2 (ar)
UY (1) UY34680A (ar)
WO (1) WO2013138586A1 (ar)
ZA (2) ZA201407440B (ar)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6002659B2 (ja) 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド ヒトｃｄ２７に結合する抗体およびその使用
BR112013021562B1 (pt) 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
WO2014140374A2 (en) * 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
FR3025517B1 (fr) * 2014-09-10 2016-12-23 Repropharm Ligands potentialisants de la bioactivite des gonadotrophines
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
PE20181367A1 (es) * 2015-09-30 2018-08-27 Janssen Biotech Inc Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
KR102908806B1 (ko) 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
EP3364995B1 (en) * 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
WO2017117384A1 (en) 2015-12-31 2017-07-06 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
JOP20190055A1 (ar) * 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
CN108473586B (zh) * 2016-09-29 2021-09-03 江苏恒瑞医药股份有限公司 抗cd27抗体、其抗原结合片段及其医药用途
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
BR112019012950A2 (pt) * 2016-12-23 2019-11-26 Macrogenics, Inc. molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3648757A4 (en) * 2017-07-03 2020-11-25 Development Center for Biotechnology ANTI-VEGFR ANTIBODIES AND ITS USES
WO2019037131A1 (zh) * 2017-08-25 2019-02-28 深圳市博奥康生物科技有限公司 一种cd27真核表达载体的构建及其高表达细胞株的制备
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2019156223A1 (ja) * 2018-02-09 2019-08-15 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
JP2021519088A (ja) * 2018-03-28 2021-08-10 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． 抗ｃｄ２７抗体、その抗原結合フラグメント及びその医学的使用
EP3774903A1 (en) * 2018-04-04 2021-02-17 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
CN111971303B (zh) * 2018-04-13 2022-05-17 苏州丁孚靶点生物技术有限公司 抗cd27抗体及其用途
KR20210011919A (ko) * 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
US20200063100A1 (en) 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
US20220016168A1 (en) 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
WO2020185952A1 (en) * 2019-03-11 2020-09-17 xCella Biosciences, Inc. Cd27-binding antibodies and uses thereof
CA3138633A1 (en) 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
AU2020283742A1 (en) * 2019-05-24 2021-09-16 Elixiron Immunotherapeutics (hong Kong) Limited Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof
CN114341365A (zh) * 2019-08-30 2022-04-12 詹森生物科技公司 B细胞成熟复合物car t构建体和引物
AU2020382219A1 (en) 2019-11-13 2022-05-12 Crispr Therapeutics Ag Manufacturing process for making T cells expressing chimeric antigen receptors
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
AU2020438234A1 (en) 2020-03-27 2022-09-29 Inflarx Gmbh Inhibitors of C5a for the treatment of corona virus infection
TW202208427A (zh) * 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CN116120451A (zh) * 2021-06-17 2023-05-16 南京蓝盾生物科技有限公司 抗cd70内化的抗体、抗体偶联物及其应用
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN116262788B (zh) * 2021-12-15 2026-05-15 泰泽惠康生物医药有限责任公司 抗cd27抗体分子
CA3259975A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CN115165829B (zh) * 2022-06-29 2025-07-29 上海交通大学 一种定量分析系统性红斑狼疮免疫细胞与功能蛋白的方法及其应用
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
CN118667002A (zh) * 2023-03-16 2024-09-20 上海赛金生物医药有限公司 抗cd27单克隆抗体及其应用
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
CN119661718B (zh) * 2025-02-20 2025-06-06 杭州华大生命科学研究院 一种抗cd27纳米抗体及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
EP1263788A2 (en) 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US6982361B1 (en) 2000-02-25 2006-01-03 The Regents Of The University Of California Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
JP2005512962A (ja) 2001-09-20 2005-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｐｄｇｆ抗体および設計抗体の産生方法
AU2003210266A1 (en) 2002-02-14 2003-09-04 Bioinvent International Ab Treatment, diagnosis and imaging of disease
EP2196474A3 (en) 2003-02-14 2010-12-15 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
EP1891113A2 (en) 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
EP2090320A1 (en) 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof
CA2729567C (en) * 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
WO2010080463A1 (en) * 2008-12-18 2010-07-15 Imclone Llc Antibody humanization
AU2010339359A1 (en) * 2009-12-29 2012-07-26 Kyowa Hakko Kirin Co., Ltd. Anti-CD27 antibody
JP6002659B2 (ja) * 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド ヒトｃｄ２７に結合する抗体およびその使用
CA2804550C (en) * 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27

Also Published As

Publication number Publication date
MX2014011100A (es) 2014-12-05
US9683046B2 (en) 2017-06-20
CA2867299C (en) 2019-08-27
NZ629697A (en) 2017-01-27
US20190248910A1 (en) 2019-08-15
TW201730214A (zh) 2017-09-01
ZA201500887B (en) 2016-01-27
CA2867299A1 (en) 2013-09-19
EA030828B1 (ru) 2018-10-31
US10301392B2 (en) 2019-05-28
AU2013232087B2 (en) 2018-02-08
PH12014502011B1 (en) 2018-08-08
ZA201407440B (en) 2016-07-27
TWI576354B (zh) 2017-04-01
US9102737B2 (en) 2015-08-11
UA121844C2 (uk) 2020-08-10
CN104284678A (zh) 2015-01-14
EP2825200A4 (en) 2015-08-26
GT201400193A (es) 2017-06-14
US10689453B2 (en) 2020-06-23
MY175224A (en) 2020-06-16
AU2013232087A1 (en) 2014-09-25
JP6487839B2 (ja) 2019-03-20
WO2013138586A1 (en) 2013-09-19
US20130243795A1 (en) 2013-09-19
SG11201405437QA (en) 2014-10-30
PH12014502011A1 (en) 2014-11-24
EA201491700A1 (ru) 2015-02-27
PE20142242A1 (es) 2015-01-08
SG10201710574UA (en) 2018-02-27
TW201345922A (zh) 2013-11-16
US20150299330A1 (en) 2015-10-22
KR102153374B1 (ko) 2020-09-10
JP2015511965A (ja) 2015-04-23
US11732050B2 (en) 2023-08-22
MX363946B (es) 2019-04-09
US20170320957A1 (en) 2017-11-09
BR112014022812A2 (pt) 2017-07-18
CO7071095A2 (es) 2014-09-30
EP2825200A1 (en) 2015-01-21
UY34680A (es) 2013-09-30
PH12017501908B1 (en) 2018-10-01
CN104284678B (zh) 2018-04-24
ECSP14018641A (es) 2018-10-31
KR20140133940A (ko) 2014-11-20
US20240141055A1 (en) 2024-05-02
PH12017501908A1 (en) 2018-10-01
HK1206251A1 (en) 2016-01-08
BR122020002414B1 (pt) 2022-03-03
CR20140415A (es) 2014-11-18
US20200277393A1 (en) 2020-09-03
CL2014002416A1 (es) 2015-01-16
AR090356A1 (es) 2014-11-05

Similar Documents

Publication Publication Date Title
PH12017501908A1 (en) Human anti-cd27 antibodies, methods and uses
PH12012502215A1 (en) Anti-fgfr2 antibodies
EA033400B1 (ru) Антитело против cd3 и его применение
EA201690567A1 (ru) Антитела против pd1 и их применение в качестве терапевтических и диагностических средств
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
HK1216850A1 (zh) 抗ntb-a抗體及相關的組合物和方法
MX2019009654A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
MX2013006100A (es) Agente terapeutico que induce citotoxicidad.
MX2020012426A (es) Anticuerpos anti-cd38.
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
WO2012102753A3 (en) Metalloproteinase oligopeptides and their therapeutic use
HK1179516A (en) Anti-fgfr2 antibodies
陈若琨 et al. RRP22, a new neural tumor suppressor for gliomas
WO2014172653A3 (en) Anti-notch1 antibodies
EA201992798A2 (ru) Антитела против pd1 и их применение в качестве терапевтических и диагностических средств
TN2013000265A1 (en) Anti-cd38 antibodies
PH12013501424B1 (en) Anti-cd38 antibodies